Bios Life launches with $25M and Tempus alliance to reinvent cancer surveillance

Bios Life emerged from stealth with $25 million in seed funding and a multi-year partnership with Tempus to build AI-driven cancer screening and survivorship care. The Boston startup plans to launch its virtual care platform in the U.S. in the second half of 2026.

Why it matters: - Bios Life is targeting more than 40 million people in the U.S. who are at elevated cancer risk or are cancer survivors. - The company is betting that continuous, personalized surveillance can replace fragmented and reactive screening for high-risk patients. - More than 40% of people will be diagnosed with cancer in their lifetime, and more than 30% of those cases are diagnosed at stage 3 or 4.

What happened: - Bios Life emerged from stealth on August 10, 2026, with $25 million in seed financing. - Redmile, Vsquared Ventures and Kindred Capital led the round. - A syndicate of healthcare and technology investors across the United States and Europe also backed the financing. - Bios Life announced a multi-year strategic alliance with Tempus to train and validate its predictive models. - The company is building an AI-native cancer surveillance platform for high-risk individuals and cancer survivors.

The details: - Bios Life is developing a personalized surveillance strategy that evolves with each patient over time. - The company combines advanced multi-modality foundation models with direct patient care. - Bios Life says its platform will serve individuals across the U.S. through a virtual care delivery model with licensed care teams. - The platform is designed to support cancer surveillance and holistic supportive care tailored to each person’s needs. - Bios Life describes its approach as creating a digital twin for each patient, updated continuously with biology and risk data. - The company’s core technologies include its Personalized Cancer Risk Platform and Cancer Surveillance Platform. - Bios Life holds commercial rights to the Nucleotide Transformer genomics foundation model developed by BioNTech-InstaDeep. - The model can interpret genomic signals at single-nucleotide resolution. - The model can assess the impact of genetic variation across the genome, including rare and previously uncharacterized variants. - Bios Life plans to launch its U.S. platform in the second half of 2026. - Consumers can join the waitlist now at more information.

Between the lines: - The Tempus deal gives Bios Life access to de-identified multi-modal oncology datasets for model training, validation and deployment. - The collaboration is aimed at moving diagnosis and surveillance from reactive scans to continuous predictive modeling. - Bios Life will also work with Ambry Genetics, now a Tempus company, to integrate genetic screening into its preventive platform. - The survivorship program will include physician-ordered genetic testing. - The company is positioning itself in a space that has seen little change in screening and surveillance for 20 to 30 years, according to Duke Cancer Institute’s Kevin Oeffinger. - Ryan Richardson, co-founder and CEO, said the funding and partners give Bios Life the foundation to become a category-defining company. - Ryan Fukushima, CEO of Data and Apps at Tempus, said the collaboration is meant to improve prediction, monitoring and support over a patient’s lifetime.

What's next: - Bios Life is preparing a U.S. launch in the second half of 2026. - The company will use the Tempus alliance to train and validate predictive models across a range of common cancers. - Bios Life will continue building its virtual-first care model and clinical partnerships with leading cancer centers. - Early access is available through the company waitlist.

The bottom line: - Bios Life is trying to turn cancer surveillance into a continuous, AI-guided service for people at highest risk, backed by major seed funding and a key data partnership with Tempus.